Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 6FED 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 3Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Thoracic Neoplasms 1Sarcopenia 1Recurrence 1Rectal Neoplasms 1Rare Diseases 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neurologic Manifestations 1Neoplasms by Site 1Neoplasm Metastasis 1Myasthenia Gravis 1Mental Disorders 1Lung Neoplasms 1Lung Diseases 1Liver Neoplasms 1Head and Neck Neoplasms 1Early Stage Lung Cancer (I and II) 1Condylomata Acuminata 1Colonic Polyps 1Colonic Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Bronchogenic 1Cachexia 1Breast Neoplasms 1Anxiety Disorders 1Adenomatous Polyposis Coli 1

Interventions

Immunoglobulins 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × FED × Neurologic Manifestations × Clear all
NCT00004682 2015-03-25

Randomized Study of Intravenous Immunoglobulin in Patients With Mild or Moderate Myasthenia Gravis

FDA Office of Orphan Products Development

Phase NA Terminated
100 enrolled

Mental Disorders, Myasthenia Gravis, Neurologic Manifestations, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡